213 related articles for article (PubMed ID: 28851352)
1. Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma.
Wu JF; Chang HH; Lu MY; Jou ST; Chang KC; Ni YH; Chang MH
J Biomed Sci; 2017 Aug; 24(1):62. PubMed ID: 28851352
[TBL] [Abstract][Full Text] [Related]
2. Complementary roles of β-catenin and glutamine synthetase immunostaining in diagnosis of chemotherapy-treated and untreated hepatoblastoma.
Huang WJ; Tsai JH; Jeng YM
J Formos Med Assoc; 2017 Jul; 116(7):549-553. PubMed ID: 28277286
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
[TBL] [Abstract][Full Text] [Related]
5. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
6. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.
Park WS; Oh RR; Park JY; Kim PJ; Shin MS; Lee JH; Kim HS; Lee SH; Kim SY; Park YG; An WG; Kim HS; Jang JJ; Yoo NJ; Lee JY
J Pathol; 2001 Apr; 193(4):483-90. PubMed ID: 11276007
[TBL] [Abstract][Full Text] [Related]
7. Variable antigen expression in hepatoblastomas.
Ramsay AD; Bates AW; Williams S; Sebire NJ
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):140-7. PubMed ID: 18227729
[TBL] [Abstract][Full Text] [Related]
8. Zinc finger protein X-linked promotes expansion of EpCAM
Wang C; Fu SY; Wang MD; Yu WB; Cui QS; Wang HR; Huang H; Dong W; Zhang WW; Li PP; Lin C; Pan ZY; Yang Y; Wu MC; Zhou WP
Mol Oncol; 2017 May; 11(5):455-469. PubMed ID: 28156061
[TBL] [Abstract][Full Text] [Related]
9. Relationship of β-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma.
Gupta K; Rane S; Das A; Marwaha RK; Menon P; Rao KL
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e320-8. PubMed ID: 22735888
[TBL] [Abstract][Full Text] [Related]
10. Fetal and neonatal hepatic tumors.
Isaacs H
J Pediatr Surg; 2007 Nov; 42(11):1797-803. PubMed ID: 18022426
[TBL] [Abstract][Full Text] [Related]
11. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
[TBL] [Abstract][Full Text] [Related]
12. Intracellular localization of beta-catenin expression plays a possible prognostic role on the outcome of hepatoblastoma patients.
Celtik U; Dokumcu Z; Divarci E; Guler E; Ataseven E; Nart D; Yilmaz F; Celik A; Ergün O
Pediatr Surg Int; 2020 Jul; 36(7):817-825. PubMed ID: 32436062
[TBL] [Abstract][Full Text] [Related]
13. β-Catenin mutations in 2 nested stromal epithelial tumors of the liver--a neoplasia with defective mesenchymal-epithelial transition.
Assmann G; Kappler R; Zeindl-Eberhart E; Schmid I; Häberle B; Graeb C; Jung A; Müller-Höcker J
Hum Pathol; 2012 Nov; 43(11):1815-27. PubMed ID: 22749188
[TBL] [Abstract][Full Text] [Related]
14. Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Czauderna P; Sullivan M
Eur J Cancer; 2012 Aug; 48(12):1853-9. PubMed ID: 22137595
[TBL] [Abstract][Full Text] [Related]
15. [Current status of diagnosis and treatment of hepatoblastoma].
García-Miguel P; López Santamaría M
Clin Transl Oncol; 2005 Aug; 7(7):328-34. PubMed ID: 16185597
[No Abstract] [Full Text] [Related]
16. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
Yamashita T; Budhu A; Forgues M; Wang XW
Cancer Res; 2007 Nov; 67(22):10831-9. PubMed ID: 18006828
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of beta-catenin in hepatoblastoma and its clinical significance.
Archana B; D'Cruze L; Nazneen S; Thanka J; Scott JX
J Cancer Res Ther; 2022; 18(3):677-680. PubMed ID: 35900540
[TBL] [Abstract][Full Text] [Related]
18. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.
Sha YL; Liu S; Yan WW; Dong B
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31511432
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of molecular genetic alterations in hepatoblastoma.
von Schweinitz D; Kraus JA; Albrecht S; Koch A; Fuchs J; Pietsch T
Med Pediatr Oncol; 2002 Feb; 38(2):104-8. PubMed ID: 11813174
[TBL] [Abstract][Full Text] [Related]
20. Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/β-Catenin Perspective.
Bell D; Ranganathan S; Tao J; Monga SP
Gene Expr; 2017 Feb; 17(2):141-154. PubMed ID: 27938502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
